Spots Global Cancer Trial Database for (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Official Title: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Study ID: NCT05907954
Conditions
Interventions
Study Description
Brief Summary: Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Detailed Description: Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long term follow-up (up to 3 years) to assess visual outcome, disease recurrence, and development of metastatic disease.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute, Scottsdale, Arizona, United States
UCLA Medical Center, Los Angeles, California, United States
Stanford Cancer Institute, Palo Alto, California, United States
Sarah Cannon Research Institute, Denver, Colorado, United States
University of Miami, Miami, Florida, United States
The Cancer and Hematology Centers, Grand Rapids, Michigan, United States
Northwell, Manhasset, New York, United States
Duke University Health System, Durham, North Carolina, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
St. Vincent's Health Sydney, Sydney, New South Wales, Australia
Alfred Health, Melbourne, Victoria, Australia
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Institute Curie, Paris, , France
Charite Comprehensive Cancer Center, Berlin, , Germany
University Hospital Essen - West German Cancer Center, Essen, , Germany
Instituto Nazionale Tumori di Milano, Milano, , Italy
Instituto Nazionale Tumori IRCCS - Fondazione Pascale, Naples, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, , Italy
Leiden University Medical Center, Leiden, , Netherlands
The Clatterbridge Cancer Centre NHS FT, Liverpool, , United Kingdom
University College London Hospital - NHS Foundation Trust, London, , United Kingdom
Contact Details
Name: Jasgit Sachdev, MD
Affiliation: IDEAYA Biosciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
